HLA-C and cancer: An orthogonal analysis using genomic data from a diverse set of 781 cancer cell lines yielded analogous results: higher PHBR scores for the most frequent mutations (median PHBR 3.36 for the top 10 versus 1.73 for the complete dataset), increased odds ratio using the within-patient model (1.24, P = 1.9e-13) and an effect that was also observed when using the prototypical MHC genotype (S3 Fig).